Biomarkers and methods for measuring and monitoring inflammatory disease activity
Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).
1. A method for generating protein level data for a first subject comprising:
performing at least one immunoassay on a first blood sample from the first subject to generate a first dataset comprising protein level data for at least four protein markers, wherein the at least four protein markers comprise at least four markers selected from chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); or, vascular endothelial growth factor A (VEGFA);
calculating a disease activity index score for the sample by combining the protein level data, wherein the disease activity index score tracks a clinical disease activity score determined from clinical data of a reference population of confirmed RA patients, wherein the clinical data supplies a clinical assessment comprising at least one of DAS, DAS28, DAS28-ESR, DAS28-CRP, HAQ, mHAQ, MDHAQ, physician global assessment VAS, patient global assessment VAS, pain VAS, fatigue VAS, overall VAS, sleep VAS, SDAI, CDAI, RAPID3, RAPID4, RAPID5, ACR20, ACR50, ACR70, SF-36, RAMRIS, TSS, modified TSS, Larsen, TJC, SJC, and GHA,
wherein the disease activity index score=((0.56*sqrt(PTJC)+0.28*sqrt(PSJC)+0.36*log(CRP/106+1)+(0.14*PPGHA)+0.96)*10.53)+1;
wherein the tracking of the clinical disease activity score is determined by one or more of analysis of variants (ANOVA), Bayesian networks, boosting and Ada-boosting, bootstrap aggregating or bagging, Classification and Regression Trees (CART), boosted CART, Random Forest (RF), Recursive Partitioning Trees (RPART), Curds and Whey (CW), Curds and Whey-Lasso, principal component analysis (PCA), Linear Discriminant Analysis (LDA), Eigengene Linear Discriminant Analysis (ELDA), Discriminant Function Analysis (DFA), factor rotation, Hidden Markov Models, kernel density estimation, kernel partial least squares, kernel matching pursuit, kernel Fisher's discriminate analysis, kernel principal components analysis, linear regression, Forward Linear Stepwise Regression, LASSO shrinkage and selection, Elastic Net regularization and selection, glmnet (Lasso and Electric Net-regularized generalized linear model), Logistic Regression (LogReg), meta-learner, Kth-nearest neighbor (KNN), non-linear regression, neural networks, partial least square, shrunken centroids (SC), sliced inverse regression, Standard for the Exchange of Product model data, super principal component (SPC) regression, Support Vector Machines (SVM), and Recursive Support Vector Machines (RSVM);
diagnosing or prognosing the subject as needing treatment for rheumatoid arthritis (RA) based on the protein level disease activity index score exceeding a reference value of the clinical disease activity score, wherein the diagnosis or prognosis is the same for subjects with and without comorbidities; and
administering a therapy to the subjected diagnosed or prognosed as needing treatment, the therapy comprising one or more of
administering a therapeutic compound selected from DMARDs, biologic DMARDs, non-steroidal anti-inflammatory drugs (NSAID's), and corticosteroids; and
administering bariatric surgical intervention.
2. The method of claim 1 , wherein performance of the at least one immunoassay comprises: obtaining the first blood sample, wherein the first blood sample comprises the protein markers; contacting the first blood sample with a plurality of distinct reagents; generating a plurality of distinct complexes between the reagents and markers; and detecting the complexes to generate the data.
3. The method of claim 1 , wherein the at least one immunoassay comprises a multiplex assay.
4. The method of claim 1 , wherein the at least four protein markers comprise at least five markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
5. The method of claim 1 , wherein the at least four protein markers comprise at least six markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
6. The method of claim 1 , wherein the at least four protein markers comprise at least seven markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
7. The method of claim 1 , wherein the at least four protein markers comprise at least eight markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
8. The method of claim 1 , wherein the at least four protein markers comprise at least nine markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
9. The method of claim 1 , wherein the at least four protein markers comprise at least ten markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
10. The method of claim 1 , wherein the at least four protein markers comprise at least eleven markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
11. The method of claim 1 , wherein the CHI3L1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001267.2, wherein the CRP is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000558.2, wherein the EGF is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001954.2, wherein the IL6 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000591.1, wherein the LEP is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000221.1, wherein the MMP1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_002412.1, wherein the MMP3 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_002413.1, wherein the RETN is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_065148.1, wherein the SAA1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000322.2, wherein the TNFRSF1A is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001056.1, wherein the VCAM1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001069.1, and wherein the VEGFA is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001020539.2.
12. A method for generating a protein level score comprising:
performing at least one immunoassay on a first blood sample from a first subject previously diagnosed with rheumatoid arthritis (RA), or suspected of having RA, to generate protein level data for each protein marker of a plurality of protein markers, wherein the plurality of protein markers comprises a plurality of test markers comprising at least four markers selected from chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1); C-reactive protein, pentraxin-related (CRP); epidermal growth factor (beta-urogastrone) (EGF); interleukin 6 (interferon, beta 2) (IL6); leptin (LEP); matrix metallopeptidase 1 (interstitial collagenase) (MMP1); matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3); resistin (RETN); serum amyloid A1 (SAA1); tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A); vascular cell adhesion molecule 1 (VCAM1); or, vascular endothelial growth factor A (VEGFA);
calculating a disease activity index score for the sample by combining the protein level data, wherein the disease activity index score tracks a clinical disease activity score determined from clinical data of a reference population of confirmed RA patients, wherein the clinical data supplies a clinical assessment comprising one or more of DAS, DAS28, DAS28-ESR, DAS28-CRP, TJC, SJC, and PGA,
wherein the disease activity index score=((0.56 sqrt(PTJC)+0.28*sqrt(PSJC)+0.36*log(CRP/106+1)+(0.14*PPGHA)+0.96)*10.53)+1;
wherein the tracking of the clinical disease activity score is determined by one or more of analysis of variants (ANOVA), Bayesian networks, boosting and Ada-boosting, bootstrap aggregating or bagging, Classification and Regression Trees (CART), boosted CART, Random Forest (RF), Recursive Partitioning Trees (RPART), Curds and Whey (CW), Curds and Whey-Lasso, principal component analysis (PCA), Linear Discriminant Analysis (LDA), Eigengene Linear Discriminant Analysis (ELDA), Discriminant Function Analysis (DFA), factor rotation, Hidden Markov Models, kernel density estimation, kernel partial least squares, kernel matching pursuit, kernel Fisher's discriminate analysis, kernel principal components analysis, linear regression, Forward Linear Stepwise Regression, LASSO shrinkage and selection, Elastic Net regularization and selection, glmnet (Lasso and Electric Net-regularized generalized linear model), Logistic Regression (LogReg), meta-learner, Kth-nearest neighbor (KNN), non-linear regression, neural networks, partial least square, shrunken centroids (SC), sliced inverse regression, Standard for the Exchange of Product model data, super principal component (SPC) regression, Support Vector Machines (SVM), and Recursive Support Vector Machines (RSVM);
diagnosing or prognosing the subject as needing treatment for rheumatoid arthritis (RA) based on the protein level disease activity index score exceeding a reference value of the clinical disease activity score, wherein the diagnosis or prognosis is the same for subjects with and without comorbidities; and
administering a therapy to the subjected diagnosed or prognosed as needing treatment, the therapy comprising one or more of
administering a therapeutic compound selected from DMARDs, biologic DMARDs, non-steroidal anti-inflammatory drugs (NSAID's), and corticosteroids; and administering bariatric surgical intervention.
13. The method of claim 12 , wherein performance of the at least one immunoassay comprises: obtaining the first blood sample, wherein the first blood sample comprises the protein markers; contacting the first blood sample with a plurality of distinct reagents; generating a plurality of distinct complexes between the reagents and markers; and detecting the complexes to generate the data.
14. The method of claim 12 , wherein the at least one immunoassay comprises a multiplex assay.
15. The method of claim 12 , wherein the at least four protein markers comprise at least five markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
16. The method of claim 12 , wherein the at least four protein markers comprise at least six markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
17. The method of claim 12 , wherein the at least four protein markers comprise at least seven markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
18. The method of claim 12 , wherein the at least four protein markers comprise at least eight markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
19. The method of claim 12 , wherein the at least four protein markers comprise at least nine markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
20. The method of claim 12 , wherein the at least four protein markers comprise at least ten markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
21. The method of claim 12 , wherein the at least four protein markers comprise at least eleven markers selected from CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, or VEGFA.
22. The method of claim 12 , wherein the plurality of test markers comprises CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, RETN, SAA1, TNFRSF1A, VCAM1, and VEGFA.
23. The method of claim 12 , wherein the CHI3L1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001267.2, wherein the CRP is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000558.2, wherein the EGF is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001954.2, wherein the IL6 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000591.1, wherein the LEP is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000221.1, wherein the MMP1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_002412.1, wherein the MMP3 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_002413.1, wherein the RETN is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_065148.1, wherein the SAA1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_000322.2, wherein the TNFRSF1A is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001056.1, wherein the VCAM1 is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001069.1, and wherein the VEGFA is at least 90% identical to the amino acid sequence of NCBI RefSeq NP_001020539.2.